Abstract: A process for obtaining compositions constituted by propolis nanoparticles is disclosed. The nanoparticles are optionally associated to a substance of interest such as active ingredients, and, optionally, substances of secondary effect such as synergists and adjuvants. The process includes preparing a fraction A, which consists of propolis extract dissolved in an organic solvent, to which stabilizer and/or emulsifier may be added, and, optionally, substances of interest and/or of secondary effect; ii) preparing a fraction B, aqueous phase, constituted by: (ii.1) water; or (ii.2) an aqueous solution or dispersion, to which stabilizer and/or emulsifier may be added; (iii) dropping the fraction A onto the fraction B or vice versa; iv) homogenizing the mixture by stirring and spontaneous formation of nanoparticles with average size from 1 to 1000 nm in a dispersion; and v) optionally (v-1) removing organic solvent and/or (v-2) drying the nanodispersion.

Abstract: The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.

Abstract: A process for obtaining compositions constituted by propolis nanoparticles is disclosed. The nanoparticles are optionally associated to a substance of interest such as active ingredients, and, optionally, substances of secondary effect such as synergists and adjuvants. The process includes preparing a fraction A, which consists of propolis extract dissolved in an organic solvent, to which stabilizer and/or emulsifier may be added, and, optionally, substances of interest and/or of secondary effect; ii) preparing a fraction B, aqueous phase, constituted by: (ii.1) water; or (ii.2) an aqueous solution or dispersion, to which stabilizer and/or emulsifier may be added; (iii) dropping the fraction A onto the fraction B or vice versa; iv) homogenizing the mixture by stifling and spontaneous formation of nanoparticles with average size from 1 to 1000 nm in a dispersion; and v) optionally (v-1) removing organic solvent and/or (v-2) drying the nanodispersion.

Abstract: The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.